HDR defect and may also provide the basis for new therapeutic strategies for patients with oncometabolite-producing malignancies.
Any thoughts on what else could lead to PARPi resistance in IDH-mutant cancers? 👀 Would love to hear your thoughts! 7/7 🧵
Excited that part of my thesis work was published last week in NAR Cancer!
Work from our lab and others have shown that cancers with IDH1/2 mutations have a defect in homology-directed repair (HDR), rendering them sensitive to PARP inhibitor treatment.🧵 https://t.co/APqkW1QEtt
with cediranib re-sensitized 53BP1- and REV7-knockout cells to PARP inhibitor treatment, providing insight into treatment regimens that may provide increased clinical benefits to patients! This works supports the original observation that IDH mutations confer a… 6/7 🧵
As an MD/PhD, I'm probably biased here, but I find these oversimplified generalizations hard to understand.
A quick look at any list of influential biomedical scientists (Nobel laureates, leaders across fields, big pharma CSOs, biotech founders) shows that MD/PhDs (or MDs deeply engaged in research) are prominently represented.
Many are also excellent clinicians, particularly in highly specialized or rare disease areas, where clinical insight is the often the only driver of scientific discovery.
So the claim that MD/PhDs "seldom advance either basic knowledge or clinical practice" doesn’t hold up. And the shift toward administrative or leadership roles later in one’s career isn’t unique to MD/PhDs.
Most MD/PhDs I know are among the hardest-working people in either medicine or science. They commit to 15-20 years of training and most often end up earning less than purely clinical peers.
Excited to see my PhD work out! Here, we find an unexpected epigenetic mechanism that regulates oncogene amplification to promote tyrosine kinase inhibitor resistance in lung adenocarcinoma. Tweetorial below! ⬇️
https://t.co/2AL1TMZiG0
Just received my F31 score, and I'm in awe. So ecstatic the effort was noticed. Huge thanks to the team backing me up through this process, especially my PI @BernaSozen_ 🤍 Grateful to be part of @YaleGenetics#womenshealthresearch let’s gooo!!!
Hi everybody! I am super excited to share the work done during my PhD published in @nature today! We describe a new mechanism of self- vs. non-self RNA discrimination by showing how N-glycans shield glycoRNAs from stimulating endosomal RNA sensors https://t.co/7hzGDPjvMU
🩺 Attention MD/DO-PhD trainees! 🩺
Help out pre-med students interested in the #doubledocs pathway by sharing portions of your application materials (securely hosted on the APSA website, accessible to members only)!
https://t.co/3uByySLKhi
#premed#APSA#physicianscientists
Grateful to be one of the recipients for the Pershing Square Sohn Cancer Prize from @psscra! It will greatly help our work to develop a novel vaccine for pancreatic cancer. Work was led by our post docs @nanamedici
and Diana Martinez-Saucedo! @YaleMed@YaleCancer
Officially the 1st Puerto Rican 🇵🇷 to complete the combined MD/PhD @PittCMU_MSTP. I stand on the shoulders of generations of Boricuas who fought tirelessly and whose legacy I take with me everywhere I go.
Aquí estuvimos, estamos y estaremos @uprm@PittTweet